305 related articles for article (PubMed ID: 27298402)
41. Grade 3 Follicular Lymphoma: Outcomes in the Rituximab Era.
Mustafa Ali M; Rybicki L; Nomani L; Rouphail B; Dean RM; Hill BT; Jagadeesh D; Pohlman B; Hsi ED; Smith MR
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):797-803. PubMed ID: 28789937
[TBL] [Abstract][Full Text] [Related]
42. Novel acquisitions on biology and management of transformed follicular lymphoma.
Minoia C; Zucca E; Conconi A
Hematol Oncol; 2018 Oct; 36(4):617-623. PubMed ID: 29602222
[TBL] [Abstract][Full Text] [Related]
43. Up-front rituximab maintenance improves outcome in patients with follicular lymphoma: a collaborative Nordic study.
Madsen C; Clausen MR; Plesner TL; Pasanen A; Kuismanen T; Bentzen HH; Jørgensen JM; Sillesen IB; Himmelstrup BM; Rønnov-Jessen D; Jensen KR; Pettinger AM; Ludvigsen M; Leppä S; d'Amore FA
Blood Adv; 2018 Jul; 2(13):1562-1571. PubMed ID: 29976619
[TBL] [Abstract][Full Text] [Related]
44. Yttrium 90-ibritumomab tiuxetan plus rituximab maintenance as initial therapy for patients with high-tumor-burden follicular lymphoma: a Wisconsin Oncology Network study.
Rajguru S; Kristinsdottir T; Eickhoff J; Peterson C; Meyer CM; Traynor AM; Kahl BS
Clin Adv Hematol Oncol; 2014 Aug; 12(8):509-15. PubMed ID: 25356575
[TBL] [Abstract][Full Text] [Related]
45. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study.
Herold M; Haas A; Srock S; Neser S; Al-Ali KH; Neubauer A; Dölken G; Naumann R; Knauf W; Freund M; Rohrberg R; Höffken K; Franke A; Ittel T; Kettner E; Haak U; Mey U; Klinkenstein C; Assmann M; von Grünhagen U;
J Clin Oncol; 2007 May; 25(15):1986-92. PubMed ID: 17420513
[TBL] [Abstract][Full Text] [Related]
46. Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts.
Sarkozy C; Maurer MJ; Link BK; Ghesquieres H; Nicolas E; Thompson CA; Traverse-Glehen A; Feldman AL; Allmer C; Slager SL; Ansell SM; Habermann TM; Bachy E; Cerhan JR; Salles G
J Clin Oncol; 2019 Jan; 37(2):144-152. PubMed ID: 30481079
[TBL] [Abstract][Full Text] [Related]
47. Short duration immunochemotherapy followed by radioimmunotherapy consolidation is effective and well tolerated in relapsed follicular lymphoma: 5-year results from a UK National Cancer Research Institute Lymphoma Group study.
Illidge TM; McKenzie HS; Mayes S; Bates A; Davies AJ; Pettengell R; Stanton L; Cozens K; Hampson G; Dive C; Zivanovic M; Tipping J; Gallop-Evans E; Radford JA; Johnson PW
Br J Haematol; 2016 Apr; 173(2):274-82. PubMed ID: 26849853
[TBL] [Abstract][Full Text] [Related]
48. Autologous transplantation in patients with relapsed or high-grade follicular lymphoma provides long term disease-free survival and best median duration of response.
Ganguly S; Divine CL; Deauna-Limayo D; Bodensteiner DC; Cook JD; Lewis JN; Skikne BS
Ann Hematol; 2005 Aug; 84(8):526-31. PubMed ID: 15915350
[TBL] [Abstract][Full Text] [Related]
49. Prognostic ability of five clinical risk scores in follicular lymphoma: A single-center evaluation.
Mozas P; Rivero A; Rivas-Delgado A; Correa JG; Condom M; Nadeu F; Giné E; Delgado J; Villamor N; Campo E; Magnano L; López-Guillermo A
Hematol Oncol; 2021 Dec; 39(5):639-649. PubMed ID: 34494300
[TBL] [Abstract][Full Text] [Related]
50. Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis.
Federico M; Caballero Barrigón MD; Marcheselli L; Tarantino V; Manni M; Sarkozy C; Alonso-Álvarez S; Wondergem M; Cartron G; Lopez-Guillermo A; Issa D; Morschhauser F; Alcoceba M; Kimby E; Rusconi C; Chamuleau M; Holte H; Lockmer S; Montoto S; Gomes da Silva M; Aurer I; Zucca E; Paszkiewicz-Kozik E; Minoia C; Skrypets T; Blaker YN; Salles G; Coiffier B;
Lancet Haematol; 2018 Aug; 5(8):e359-e367. PubMed ID: 30078408
[TBL] [Abstract][Full Text] [Related]
51. Follicular lymphoma in early stages: high risk of relapse and usefulness of the Follicular Lymphoma International Prognostic Index to predict the outcome of patients.
Plancarte F; López-Guillermo A; Arenillas L; Montoto S; Giné E; Muntañola A; Ferrer A; Villamor N; Bosch F; Colomo L; Balaguer O; Campo E; Montserrat E
Eur J Haematol; 2006 Jan; 76(1):58-63. PubMed ID: 16343272
[TBL] [Abstract][Full Text] [Related]
52. Obinutuzumab for the First-Line Treatment of Follicular Lymphoma.
Marcus R; Davies A; Ando K; Klapper W; Opat S; Owen C; Phillips E; Sangha R; Schlag R; Seymour JF; Townsend W; Trněný M; Wenger M; Fingerle-Rowson G; Rufibach K; Moore T; Herold M; Hiddemann W
N Engl J Med; 2017 Oct; 377(14):1331-1344. PubMed ID: 28976863
[TBL] [Abstract][Full Text] [Related]
53. Risk of histological transformation and therapy-related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma.
Epperla N; Pham AQ; Burnette BL; Wiseman GA; Habermann TM; Macon WR; Ansell SM; Inwards DJ; Micallef IN; Johnston PB; Markovic SN; Porrata LF; Colgan JP; Ristow KM; Nowakowski GS; Witzig TE
Br J Haematol; 2017 Aug; 178(3):427-433. PubMed ID: 28466487
[TBL] [Abstract][Full Text] [Related]
54. Follicular Lymphoma Evaluation Index (FLEX): A new clinical prognostic model that is superior to existing risk scores for predicting progression-free survival and early treatment failure after frontline immunochemotherapy.
Mir F; Mattiello F; Grigg A; Herold M; Hiddemann W; Marcus R; Seymour JF; Bolen CR; Knapp A; Nielsen T; Casulo C
Am J Hematol; 2020 Dec; 95(12):1503-1510. PubMed ID: 32815559
[TBL] [Abstract][Full Text] [Related]
55. The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era.
Blaker YN; Spetalen S; Brodtkorb M; Lingjaerde OC; Beiske K; Østenstad B; Sander B; Wahlin BE; Melen CM; Myklebust JH; Holte H; Delabie J; Smeland EB
Br J Haematol; 2016 Oct; 175(1):102-14. PubMed ID: 27341313
[TBL] [Abstract][Full Text] [Related]
56. Symptoms and toxicity of rituximab maintenance relative to observation following immunochemotherapy in patients with follicular lymphoma.
Zhou X; Wang J; Zhang J; Copley-Merriman C; Torigoe Y; Reyes C; Seymour JF; Offner FC; Trneny M; Salles GA
Hematology; 2015 Apr; 20(3):129-36. PubMed ID: 25029908
[TBL] [Abstract][Full Text] [Related]
57. Follicular lymphoma: 2012 update on diagnosis and management.
Freedman A
Am J Hematol; 2012 Oct; 87(10):988-95. PubMed ID: 23001911
[TBL] [Abstract][Full Text] [Related]
58. The simplified follicular lymphoma PRIMA-prognostic index is useful in patients with first-line chemo-free rituximab-based therapy.
Kimby E; Lockmer S; Holte H; Hagberg H; Wahlin BE; Brown P; Østenstad B
Br J Haematol; 2020 Dec; 191(5):738-747. PubMed ID: 32410260
[TBL] [Abstract][Full Text] [Related]
59. Refractoriness to immunochemotherapy in follicular lymphoma: Predictive factors and outcome.
Sorigue M; Mercadal S; Alonso S; Fernández-Álvarez R; García O; Moreno M; Pomares H; Alcoceba M; González-García E; Motlló C; González-Barca E; Martin A; Sureda A; Caballero D; Ribera JM; Sancho JM
Hematol Oncol; 2017 Dec; 35(4):520-527. PubMed ID: 28156010
[TBL] [Abstract][Full Text] [Related]
60. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial.
Ardeshna KM; Qian W; Smith P; Braganca N; Lowry L; Patrick P; Warden J; Stevens L; Pocock CF; Miall F; Cunningham D; Davies J; Jack A; Stephens R; Walewski J; Ferhanoglu B; Bradstock K; Linch DC
Lancet Oncol; 2014 Apr; 15(4):424-35. PubMed ID: 24602760
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
